A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient

Pediatric Transplantation

Volumn 16, Issue 6, 2012, Pages

  Maguire, Michelle ^a   Franz, Thaddeus ^b   Hains, David S ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

CYP 2C19; drug interaction; pediatric renal transplantation; pharmacogenetics; proton pump inhibitors; tacrolimus

Indexed keywords

CARVEDILOL; CEFDINIR; CREATININE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PREDNISONE; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; VALGANCICLOVIR;

ADULT; ARTICLE; CASE REPORT; CLINICAL RESEARCH; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PHYSICIAN; WEGENER GRANULOMATOSIS;

ADOLESCENT; ARYL HYDROCARBON HYDROXYLASES; DRUG INTERACTIONS; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; TACROLIMUS; TREATMENT OUTCOME;

EID: 84864624621     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01559.x     Document Type: Article

References (21)

1. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004: 43: 623-653. (Pubitemid 38981845)
2. Christians U, Jacobsen W, Benet LZ, Lampen A,. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002: 41: 813-851.
3. Itagaki F, Homma M, Yuzawa K, et al., Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J Pharm Pharmacol 2004: 56: 1055-1059. (Pubitemid 39140062)
4. Hesselink DA, Van Schaik RH, Van Der Heiden IP, et al., Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003: 74: 245-254. (Pubitemid 37083100)
5. Katsakiori PF, Papapetrou EP, Goumenos DS, Nikiforidis GC, Flordellis CS,. Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. Ther Clin Risk Manag 2010: 6: 265-269.
6. Tsuchiya N, Satoh S, Tada H, et al., Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004: 78: 1182-1187. (Pubitemid 39426437)
7. Sarkio S, Halme L, Kyllonen L, Salmela K,. Severe gastrointestinal complications after 1,515 adult kidney transplantations. Transpl Int 2004: 17: 505-510. (Pubitemid 39592737)
8. Ishizaki T, Horai Y,. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors-Emphasis on rabeprazole. Aliment Pharmacol Ther 1999: 13 (Suppl 3): 27-36. (Pubitemid 29389409)
9. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett DJ,. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993: 36: 521-530. (Pubitemid 24001713)
10. Rost KL, Roots I,. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996: 23: 1491-1497. (Pubitemid 26181233)
11. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T,. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997: 283: 434-442. (Pubitemid 27514596)
12. Klotz U,. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs). Eur J Clin Pharmacol 2009: 65: 1-2.
13. Shi S, Klotz U,. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008: 64: 935-951.
14. Li XQ, Andersson TB, Ahlstrom M, Weidolf L,. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004: 32: 821-827. (Pubitemid 38955611)
15. Rapp RP,. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998: 32: 785-793. (Pubitemid 28341111)
16. Amacher DE, Schomaker SJ, Retsema JA,. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991: 35: 1186-1190.
17. Mori T, Aisa Y, Nakazato T, Yamazaki R, Ikeda Y, Okamoto S,. Tacrolimus-azithromycin interaction in a recipient of allogeneic bone marrow transplantation. Transpl Int 2005: 18: 757-758. (Pubitemid 41726846)
18. Shullo MA, Schonder K, Teuteberg JJ,. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: A case report. Transplant Proc 2010: 42: 1870-1872.
19. Niwa T, Shiraga T, Hashimoto T, Kagayama A,. Effect of cefixime and cefdinir, oral cephalosporins, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 2004: 27: 97-99. (Pubitemid 41656681)
20. Moreau C, Debray D, Loriot MA, Taburet AM, Furlan V,. Interaction between tacrolimus and omeprazole in a pediatric liver transplant recipient. Transplantation 2006: 81: 487-488. (Pubitemid 43255741)
21. Hosohata K, Masuda S, Katsura T, et al., Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos 2009: 37: 821-826.